Ongoing treatment depends on: Continued clinical benefit Safety and tolerability Remaining within eligibility criteria defined by the PGD GLP-1 medicines are not intended to be lifelong by default , and all patients are reviewed regularly
Western Blot Total proteins were extracted in RIPA buffer (Sigma-Aldrich) that was supplemented with protease inhibitor cocktail (100 Sigma-Aldrich)
The responses to this question were almost identical to the previous question with the selected symptoms being vomiting (86%, n = 200), nausea (70%, n = 162), fullness (54%, n = 126), bloating (53%, n = 124), then upset stomach (46%, n = 108), lethargy (18%, n = 43), dizziness (14%, n = 32), other (9%, n = 20), loss of appetite (9%, n = 20), none (7%, n = 16), and headache (2%, n = 4) (Tables 6-8)
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)
